Home / Leaderboard / Paradigm Biocapital Advisors LP
Paradigm Biocapital Advisors LP
Senai Asefaw · Hedge Fund · Long/Short Equity
Paradigm Biocapital Advisors LP is a New York-based investment management firm founded in July 2020 by Dr. Senai Asefaw. The firm specializes in the biotechnology and life sciences sectors, managing a diversified portfolio of both public and private healthcare investments. It operates as a sector-focused hedge fund manager, targeting companies involved in significant biomedical innovation and breakthrough therapeutic advancements to achieve attractive risk-adjusted returns.
Simulated Performance
| Metric | Value |
|---|---|
| Total return | +130.6% |
| YTD return | +54.5% |
| Sharpe ratio | 4.35 |
| Win rate | 64% |
| AUM | $4.4B |
| Inception | Oct 1, 2025 |
| Updated | Aug 20, 2026 |
Institution Status
| Field | Value |
|---|---|
| AUM | $4.4B |
| Turnover | Low (<15%) |
| Avg holding | 18 Months |
| Inception | Oct 1, 2025 |
| Website | https://paradigmbiocapital.com/ |
Current Holdings
Updated on Aug 20, 2026.
| Ticker | Name | Portfolio % | Return |
|---|---|---|---|
| RVMD | Revolution Medicines Inc | 30.0% | +99.0% |
| EWTX | Edgewise Therapeutics Inc | 7.2% | +73.1% |
| PCVX | Vaxcyte Inc | 6.2% | +30.3% |
| GMAB | Genmab AS | 5.6% | +13.3% |
| ORKA | Oruka Therapeutics, Inc. | 5.1% | +106.4% |
| SYRE | Spyre Therapeutics Inc. | 4.6% | +83.7% |
| ERAS | Erasca Inc | 4.3% | +75.9% |
| BLTE | Belite Bio Inc ADR | 4.1% | +14.6% |
| APGE | Apogee Therapeutics, Inc. Common Stock | 4.1% | +104.5% |
| TARS | Tarsus Pharmaceuticals Inc | 3.8% | +20.2% |
| MBX | MBX Biosciences, Inc. Common Stock | 3.7% | +14.0% |
| INSM | Insmed Inc | 3.6% | +17.8% |
| VRDN | Viridian Therapeutics Inc | 2.9% | +25.4% |
| CYTK | Cytokinetics Inc | 2.6% | -0.2% |
| TNGX | Tango Therapeutics Inc | 2.5% | +6.9% |
| ABVX | Abivax SA American Depositary Shares | 2.3% | +20.9% |
| OLMA | Olema Pharmaceuticals Inc | 2.2% | -15.4% |
| URGN | UroGen Pharma Ltd | 1.8% | +15.8% |
| MAZE | Maze Therapeutics, Inc. Common Stock | 1.7% | +8.4% |
| JBIO | Jade Biosciences, Inc. | 1.5% | -3.3% |
Recent activity
| Date | Action | Ticker | Weight |
|---|---|---|---|
| Aug 10, 2026 | BUY | ERAS | 4.8% → 4.3% |
| Aug 10, 2026 | BUY | OLMA | 2.2% → 2.2% |
| Aug 10, 2026 | BUY | BLTE | 4.0% → 4.1% |
| Aug 10, 2026 | SELL | EWTX | 7.1% → 7.2% |
| Aug 10, 2026 | SELL | MIRM | 1.8% → 0.0% |
Investment Style Analysis
Paradigm Biocapital Advisors LP is widely recognized for employing a Long/Short Equity strategy. As of Aug 20, 2026, the firm oversees approximately $4.4B in assets under management (AUM). The portfolio demonstrates a clear preference for the Biotechnology sectors, reflecting a high-conviction approach to capital allocation.
Recent Market Moves
During the latest rebalancing period ending Aug 10, Paradigm Biocapital Advisors LP made a significant move by increasing exposure to ERAS. This adjustment aligns with the fund's dynamic approach to risk management and capital deployment in current market conditions.
Investment Philosophy
The firm's investment philosophy is centered on rigorous fundamental research and deep scientific due diligence to identify high-conviction opportunities within the biotechnology landscape. By focusing on companies poised for significant medical breakthroughs, the firm employs a sector-specific strategy that utilizes both long and short positions. The approach emphasizes qualitative and quantitative analysis of clinical data, management quality, and financial health to build a concentrated portfolio aimed at long-term value creation while maintaining a focus on risk management and capital preservation.
Disclaimer
The content provided on this page, including the simulated portfolio performance, holdings analysis, and AI-generated insights, is for informational and educational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell any securities. All data is derived from historical SEC 13F filings and other public disclosures, which have a reporting lag. The "Simulated Performance" is a hypothetical reconstruction based on past disclosures and does not represent the actual returns of the institution. Past performance is not indicative of future results. Tritonix.ai is not affiliated with Paradigm Biocapital Advisors LP.
Similar Investment Style
Based on Long/Short Equity.
- Perceptive Advisors LLC — Joseph Edelman · 3M +24.1%
- Glenview Capital Management, LLC — Larry Robbins · 3M +14.0%
- Zweig-DiMenna Associates, Inc. — Joseph DiMenna · 3M +3.7%
- Redmile Group, LLC — Jeremy Green · 3M +19.6%
Frequently asked questions
How is the simulated portfolio for Paradigm Biocapital Advisors LP constructed?
This simulation is powered by Tritonix AI using official SEC filings. We focus on the "Best Ideas" by filtering for only the Top 20 largest holdings and rebalancing them to 100%. The simulation tracks performance starting from Oct 1, 2025. Our AI monitors for updates every Monday to capture major shifts. This concentrated approach highlights the manager's true stock-picking skill and mirrors their actual investment returns.
What is Paradigm Biocapital Advisors LP's largest holding?
As of the latest filing, Paradigm Biocapital Advisors LP's top position is Revolution Medicines Inc (RVMD), representing 30.0% of the portfolio. This reflects a high-conviction bet by the institution.
What is Paradigm Biocapital Advisors LP's historical performance and risk profile?
Our simulation indicates a total return of +130.6% with a win rate of 64%. Notably, the portfolio maintains a Sharpe Ratio of 4.35, suggesting an exceptional level of risk-adjusted returns compared to the broader market.
What sectors does Paradigm Biocapital Advisors LP primarily invest in?
Paradigm Biocapital Advisors LP has a strong preference for the Biotechnology sector, which makes up 100.0% of their disclosed assets. The portfolio also has exposure to other industries, indicating a specific thematic focus.
Is Paradigm Biocapital Advisors LP's portfolio concentrated or diversified?
Paradigm Biocapital Advisors LP runs a moderately concentrated portfolio with 20 disclosed positions. The top 3 holdings alone account for 43.4% of the total portfolio weight, suggesting a strategy that favors broader market exposure.
How has Paradigm Biocapital Advisors LP performed in 2026?
Our AI-simulated model portfolio for Paradigm Biocapital Advisors LP tracks a Year-to-Date (YTD) return of +54.5%. This metric helps investors gauge the institution's effectiveness in the current market environment.
Does Senai Asefaw manage Paradigm Biocapital Advisors LP directly?
Yes, Senai Asefaw serves as the key portfolio manager for Paradigm Biocapital Advisors LP, overseeing the investment strategy and final capital allocation decisions.